TURKISH JOURNAL OF HEMATOLOGY

More documents

Recommendations

Info

Wang H, et al: Bortezomib-based Regimen Improve Survival of PCLTurk J Hematol 2020;37:91-97infectious events occurred in 20%, 21%, and 16%. As our studyincluded more sPCL patients and older patients, our incidencesof infection and neurological adverse events were relativelyhigher.ConclusionOur data from a relatively high number of PCL patients haveshown that treatment with BBRs is highly effective and safe incases of PCL. BBRs and patients’ high-quality responses could beindependent predictors for OS in PCL patients. BBRs are amongthe best therapeutic options for PCL patients, which couldcontribute to both therapeutic response and further overallsurvival. However, the defects of this study lie in the lack ofdata from ASCT PCL patients, which leads to weaker survivaldata than in other works. The conclusion is still required to bevalidated in studies with further large numbers of PCL patients.With novel drugs arising, new management approaches for bothprimary and secondary PCL will appear for deeper response andlonger survival.EthicsEthics Committee Approval: This study was conducted inaccordance with the World Medical Association Declaration ofHelsinki and approved by the Ethics Committee of Beijing Chao-Yang Hospital, Capital Medical University.Informed Consent: Informed consent was obtained from allparticipants included in the study.Authorship ContributionsConcept: H.W., H.Z., Z.Z., C.G., W.C.; Design: H.W., H.Z., Z.Z., C.G.,W.C.; Data Collection or Processing: H.W., H.Z., Z.Z., C.G., W.C.;Analysis or Interpretation: H.W., H.Z., Z.Z., C.G., W.C.; LiteratureSearch: H.W., H.Z., Z.Z., C.G., W.C.; Writing: H.W., H.Z., Z.Z., C.G.,W.C.Conflict of Interest: No conflict of interest was declared by theauthors.Financial Disclosure: The authors declared that this studyreceived no financial support.Acknowledgments: This study was funded by the NationalNatural Science Foundation of China (No. 81500164).References1. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T,Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K, Greipp PR,Dispenzieri A, Lacy MQ, Rajkumar SV, Bergsagel PL, Stewart AK, FonsecaR. Genetic aberrations and survival in plasma cell leukemia. Leukemia2008;22:1044-1052.2. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases.Arch Intern Med 1974;133:813-818.3. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy.Am J Med 1987;83:1062-1068.4. Mina R, D’Agostino M, Cerrato C, Gay F, Palumbo A. Plasma cell leukemia:update on biology and therapy. Leuk Lymphoma 2017;58:1538-1547.5. D’Arena G, Valentini CG, Pietrantuono G, Guariglia R, Martorelli MC,Mansueto G, Villani O, Onofrillo D, Falcone A, Specchia G, Semenzato G,Di Renzo N, Mastrullo L, Venditti A, Ferrara F, Palumbo A, Pagano L, MustoP. Frontline chemotherapy with bortezomib-containing combinationsimproves response rate and survival in primary plasma cell leukemia: aretrospective study from GIMEMA Multiple Myeloma Working Party. AnnOncol 2012;23:1499-1502.6. Katodritou E, Terpos E, Kelaidi C, Kotsopoulou M, Delimpasi S, KyrtsonisMC, Symeonidis A, Giannakoulas N, Stefanoudaki A, Christoulas D,Chatziaggelidou C, Gastari V, Spyridis N, Verrou E, Konstantinidou P, ZervasK, Dimopoulos MA. Treatment with bortezomib-based regimens improvesoverall response and predicts for survival in patients with primary orsecondary plasma cell leukemia: analysis of the Greek Myeloma StudyGroup. Am J Hematol 2014;89:145-150.7. Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, MacroM, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, WetterwaldM, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG,Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H,Marolleau JP. Bortezomib, doxorubicin, cyclophosphamide, dexamethasoneinduction followed by stem cell transplantation for primary plasma cellleukemia: a prospective phase II study of the Intergroupe Francophone duMyelome. J Clin Oncol 2016;34:2125-2132.8. Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F,Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, GuarigliaR, D’Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, CavalliM, Pietrantuono G, Villani O, Bringhen S, Omede P, Lerose R, Agnelli L,Todoerti K, Neri A, Boccadoro M, Palumbo A. Lenalidomide and lowdosedexamethasone for newly diagnosed primary plasma cell leukemia.Leukemia 2014;28:222-225.9. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N,Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, HajekR, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A,Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, BoccadoroM; International Myeloma Working Group. Monoclonal gammopathy ofundetermined significance (MGUS) and smoldering (asymptomatic) multiplemyeloma: IMWG consensus perspectives risk factors for progression andguidelines for monitoring and management. Leukemia 2010;24:1121-1127.10. Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, VesoleDH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A,Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, BadrosAZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A,Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R,Merlini G, Lahuerta JJ, Bladé J, Orlowski RZ, Shah JJ; International MyelomaWorking Group. Plasma cell leukemia: consensus statement on diagnosticrequirements, response criteria and treatment recommendations by theInternational Myeloma Working Group. Leukemia 2013;27:780-791.11. Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D. Primary plasma cellleukemia: a Surveillance, Epidemiology, and End Results database analysisbetween 1973 and 2004. Cancer 2009;115:5734-5739.12. Sher T, Miller KC, Deeb G, Lee K, Chanan-Khan A. Plasma cell leukaemia andother aggressive plasma cell malignancies. Br J Haematol 2010;150:418-427.13. Colovic M, Jankovic G, Suvajdžic N, Milic N, Dorcevic V, Jankovic S. Thirtypatients with primary plasma cell leukemia: a single center experience.Medical Oncology 2008;25:154-160.14. Pagano L, Valentini CG, De Stefano V, Venditti A, Visani G, Petrucci MT,Candoni A, Specchia G, Visco C, Pogliani EM, Ferrara F, Galieni P, Gozzetti A,Fianchi L, De Muro M, Leone G, Musto P, Pulsoni A; GIMEMA-ALWP (Gruppo96
Turk J Hematol 2020;37:91-97Wang H, et al: Bortezomib-based Regimen Improve Survival of PCLItaliano Malattie EMatologiche dell’Adulto, Acute Leukemia Working Party:coordinator Sergio Amadori). Primary plasma cell leukemia: a retrospectivemulticenter study of 73 patients. Ann Oncol 2011;22:1628-1635.15. Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, BerensonJR, Bird JM, Dispenzieri A, Gajewski JL, Gale RP, Holmberg L, Kumar S, KyleRA, Lazarus HM, Lonial S, Mikhael J, Milone GA, Munker R, Nath R, SaccaroS, To LB, Vogl DT, Wirk B, Hari P. Hematopoietic cell transplantation forprimary plasma cell leukemia: results from the Center for InternationalBlood and Marrow Transplant Research. Leukemia 2012;26:1091-1097.16. Esparís‐Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J,Schenkein D, Pandiella A, San Miguel JF. Bortezomib is an efficient agent inplasma cell leukemias. Int J Cancer 2005;114:665-667.17. van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG. How I treatplasma cell leukemia. Blood 2012;120:2376-2389.18. Katodritou E, Verrou E, Gastari V, Hadjiaggelidou C, Terpos E, Zervas K.Response of primary plasma cell leukemia to the combination of bortezomiband dexamethasone: do specific cytogenetic and immunophenotypiccharacteristics influence treatment outcome? Leuk Res 2008;32:1153-1156.19. Saccaro S, Fonseca R, Veillon DM, Cotelingam J, Nordberg ML, Bredeson C,Glass J, Munker R. Primary plasma cell leukemia: report of 17 new casestreated with autologous or allogeneic stem-cell transplantation and reviewof the literature. Am J Hematol 2005;78:288-294.20. Libby E, Candelaria-Quintana D, Moualla H, Abdul-Jaleel M, RabinowitzI. Durable complete remission of primary plasma cell leukemia with thebortezomib plus melphalan and prednisone (VMP) regimen. Am J Hematol2010;85:733-734.21. Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D, Ochoa-Bayona JL, Kharfan-Dabaja MA, Baz R. Clinical outcomes of patients withplasma cell leukemia in the era of novel therapies and hematopoieticstem cell transplantation strategies: a single-institution experience. ClinLymphoma Myeloma Leuk 2011;11:507-511.22. Ali R, Beksac M, Ozkalemkas F, Ozkocaman V, Ozkan A, Ozcelik T, Tunali A.Efficacy of bortezomib in combination chemotherapy on secondary plasmacell leukemia. Leuk Lymphoma 2007;48:1426-1428.23. Katodritou E, Terpos E, Delimpasi S, Kotsopoulou M, Michalis E, VadikoliaC, Kyrtsonis MC, Symeonidis A, Giannakoulas N, Vadikolia C, MichaelM, Kalpadakis C, Gougopoulou T, Prokopiou C, Kaiafa G, Christoulas D,Gavriatopoulou M, Giannopoulou E, Labropoulou V, Verrou E, Kastritis E,Konstantinidou P, Anagnostopoulos A, Dimopoulos MA. Real-world data onprognosis and outcome of primary plasma cell leukemia in the era of novelagents: a multicenter national study by the Greek Myeloma Study Group.Blood Cancer J 2018;8:31.24. Mina R, Joseph NS, Kaufman JL, Gupta VA, Heffner LT, Hofmeister CC,Boise LH, Dhodapkar MV, Gleason C, Nooka AK, Lonial S. Survival outcomesof patients with primary plasma cell leukemia (pPCL) treated with novelagents. Cancer 2019;125:416-423.25. Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, GozzettiA, Grzasko N, Milunovic V, Hus I, Madry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Debski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D,Charlinski G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, WaageA, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J,Vesole DH. Secondary plasma cell leukemia: a multicenter retrospectivestudy of 101 patients. Leuk Lymphoma 2019;60:118-123.97
Page 1: Volume 37 Issue 2June 2020E-ISSN: 1
Page 4 and 5: Contact InformationEditorial Corres
Page 6 and 7: TURKISH JOURNAL OF HEMATOLOGYINSTRU
Page 8 and 9: important findings should be highli
Page 10 and 11: Full instructions and support are a
Page 12 and 13: Letters to the Editor125 Percentage
Page 14 and 15: Fodil M and Zemani F: Inhibitor Dev
Page 20 and 21: RESEARCH ARTICLEDOI: 10.4274/tjh.ga
Page 22 and 23: Okay M, et al: Splenic Marginal Zon
Page 28 and 29: Wang H, et al: Bortezomib-based Reg
Page 30 and 31: Wang H, et al: Bortezomib-based Reg
Page 36 and 37: Küçükcankurt F, et al: PTEN and
Page 38 and 39: Küçükcankurt F, et al: PTEN and
Page 42 and 43: Li M, et al: Expression Profile of
Page 48 and 49: Paviglianiti A: Metabolic Diseases
Page 50 and 51: Paviglianiti A: Metabolic Diseases
Page 52 and 53: BRIEF REPORTDOI: 10.4274/tjh.galeno
Page 54 and 55: Çiftçiler R, et al: The Impact of
Page 56 and 57: Çiftçiler R, et al: The Impact of
Page 58 and 59: Safaei A, et al: Rare Chromosomal A
Page 60 and 61: Kumar C, et al: Erythroblastic Isla
Page 62 and 63: LETTERS TO THE EDITORTurk J Hematol

TURKISH JOURNAL OF HEMATOLOGY

Create successful ePaper yourself

Delete template?

Save as template?